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with fewer cases of bleeding. Apart from the clinical effects,
it is unknown how treatment with oral anticoagulants 
and aspirin after infrainguinal bypass grafting surgery leads
to different results in the quality of life of patients and 
the costs of treatment. Treatment with oral anticoagulants is
associated with higher costs and more inconvenience for 
the patients than aspirin treatment, because of the necessity
of monitoring and adjusting the anticoagulant dose in each
patient. However, the extra costs and adverse effects of 
oral anticoagulant treatment should be considered in rela-
tion to the total costs and beneficial effects of the entire
treatment path.
The objective of this study, which was part of the Dutch
BOA Study, was to compare quality of life and costs after
infrainguinal bypass surgery in patients treated with either
oral anticoagulants or aspirin. Because of the opposite
effects of the two treatments in patients with autologous
vein grafts and nonvenous grafts, an additional subgroup
analysis was performed for these groups of patients.
METHODS
Patients. The Dutch BOA Study was a multicenter
randomized trial designed to compare the effectiveness of
oral anticoagulants and aspirin in preventing occlusions of
infrainguinal bypass grafts and the composite event of vas-
cular death, myocardial infarction, stroke, or amputation.
Until recently, it was not clear whether oral anticoagu-
lants or aspirin was the optimal treatment after infrainguinal
bypass surgery. The choice of treatment was made on the
basis of a few trials that compared antithrombotic therapies
and indirect evidence from studies in patients with other
manifestations of atherosclerotic disease.1 Recently, the
Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study
found no overall difference in treatment effect between oral
anticoagulants and aspirin.2 Oral anticoagulants were found
to be the optimal treatment for preventing autologous vein
graft occlusion and were more effective than aspirin in
reducing ischemic events. Aspirin was the optimal treatment
for preventing nonvenous graft occlusion and was associated
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The background, design, and results of the trial have been
reported elsewhere.2 In brief, all patients who required an
infrainguinal bypass graft for obstructive arterial disease
were eligible for inclusion, with only a limited number of
exclusion criteria. Between April 1995 and March 1998,
2650 patients from 77 centers were randomized to receive
either oral anticoagulants (n = 1326) or 80 mg of aspirin
daily. Oral anticoagulant treatment consisted of phenpro-
coumon or acenocoumarol, depending on the surgeons’
preference, with a target international normalized ratio of
3.0 to 4.5. All patients gave written informed consent.
The model. A model was designed that enabled the
incorporation of data from all 2650 patients in the cost-
effectiveness analysis, whereas costs and quality of life val-
ues were measured in two samples of these patients. The
model was entirely driven by the clinical outcome events
of graft occlusion, vascular intervention, amputation,
(nonfatal) myocardial infarction, (nonfatal) stroke, major
hemorrhage, and (vascular) death. According to the
event(s) patients experienced, they were assigned to a cer-
tain “health state.” All patients started in the health state
of “no additional event after the initial bypass surgery.”
Patients remained in this state until they experienced a
clinical outcome event. Patients then moved to the health
state associated with this event, for instance, the health
state “after myocardial infarction.” Each health state was
associated with fixed estimates of quality of life and costs
per day. During the time a patient remained in a certain
health state, the patient was assigned the costs and quality
of life corresponding with that particular state. If a patient
experienced more events, the patient moved to the health
state corresponding with the last event only when the last
event was more severe (ie, when it was associated with
higher costs and lower quality of life than any of the ear-
lier events). If the last event was less severe, the patient
remained in the original health state.
Data collection. The model-input consisted of the
clinical outcome events, the time until the first event, and
the quality of life and costs associated with each health
state. Clinical outcome events as defined and the time
until the first event were collected for all patients in the
study. Costs and quality of life were not measured in all
patients, but estimates of costs and quality of life associ-
ated with each health state were collected from two sam-
ples of patients. The first sample consisted of the first 409
consecutive patients with patent grafts who entered the
trial as of November 1995. These patients received a
mailed questionnaire at 3 months and subsequently every
6 months until the end of the study, 30 months after ran-
domization. The second sample consisted of 609 patients
who experienced a clinical event and who were not already
part of the first sample. From the moment the event was
reported, these patients received a questionnaire on the
same schedule as the first group. Incomplete question-
naires were returned to the patients for completion. Any
answers still missing after the questionnaire had been
returned to the trial office were completed by means of a
telephone call. Data of patients were included only when
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complete resource use and quality of life data of at least 1
month were available.
Health outcomes. Health outcomes were measured
for event-free survival and quality-adjusted life-years
(QALYs). Event-free survival was defined as the mean
time a patient remained in the study without experiencing
a clinical outcome event. QALYs were calculated by mul-
tiplying the time a patient remained in a certain health
state by the quality of life value associated with that par-
ticular state and subsequent summing over all health
states. Quality of life values only depended on the preced-
ing events and were independent from treatment group.
Quality of life values associated with each health state were
derived from the two samples of patients described. The
first sample yielded quality of life estimates of the health
state in which patients experienced no clinical outcome
event other than the initial bypass grafting procedure.
Both samples were used as a means of obtaining quality of
life values of the health states after any of the other clini-
cal outcome events. Quality of life values were measured
with the EuroQol questionnaire (EQ-5D). The EQ-5D
results in a single numeric value that represents health sta-
tus. A value of 1 represents normal health, whereas 0 rep-
resents death.3 The analysis of the quality of life data was
published in detail in this journal.4,5
Costs. In calculating the costs per patient, a distinc-
tion was made in three categories: “health state-related
costs,” “event-related costs,” and the costs of study med-
ication. Health state-related costs reflected the costs of
health care resource use in the period after an event.
These costs were assigned to a patient for each month the
patient remained in a certain health state. Estimates of the
costs per month for each health state were based on
resource use of the two samples defined. In each ques-
tionnaire, we asked for the number of days in the hospi-
tal, nursing home, rehabilitation center, or other
inpatient setting, the number of outpatient visits to the
consultant, general practitioner, and physiotherapist, and
the number of hours of home-care in the last month. The
mean resource use was multiplied with fixed unit costs, as
described in Appendix II. This data collection resulted in
estimates of the monthly costs associated with each health
state after an event, including the health state in which
patients had experienced no other clinical event after the
initial bypass surgery.
Health care costs at the time of an event were higher
than in the months after an event. To incorporate these
higher costs at the time of an event in the model, we dis-
tinguished a second cost category: the event-related costs.
Event-related costs contained the costs of hospitalization
directly after an event and, when applicable, the costs of
the (surgical) intervention. These event-related costs were
assigned to a patient each time the patient experienced an
event, irrespective of the number or severity of earlier
events. Because all patients underwent an initial bypass
grafting procedure, the costs of the first intervention at
randomization were not included. Like quality of life val-
ues, similar estimates of the health state- and event-related
costs were used in both treatment groups. In cases of lim-
ited data, cost estimates were complemented with data
from earlier publications.6,7
Costs of study medication, aspirin or oral anticoagu-
lants, were based on 1996 list prices and enlarged with the
pharmacists’ fee. The costs of monitoring patients with
oral anticoagulant treatment were determined by means of
a costing study in three anticoagulation clinics.8 The extra
costs of monitoring in the anticoagulant group consisted
of 25 visits to the anticoagulation clinic per year, with a
mean cost of ` 8 per visit. Costs of aspirin included the
prescription costs of the general practitioner, consisting of
four telephone consultations per year. All costs were cal-
culated in Dutch guilders and converted to Euros (fl.2.20
= ` 1.00 = US $ 0.93).
Analysis. Costs and health outcomes were presented
as the mean outcomes per patient. Incremental cost-
effectiveness ratios (CE-ratios) were defined as the differ-
ence in costs divided by the difference in event-free sur-
vival and QALYs. In accordance with earlier publications,
ratios were calculated only in cases of a significant differ-
ence in costs or effects between treatment groups.9
Bootstrapping was used as a means of determining the
95% CIs around the means of these ratios. The bootstrap
method is a means of estimating the sampling distribution
of a statistic (in this case, the CE-ratio) through a large
number of simulations, on the basis of sampling with
replacement from the original data.10,11 A further expla-
nation of bootstrapping is presented in Appendix III. In
this study, we performed a bootstrap with 1000 replica-
tions. To express the uncertainty around the CE-ratio, 
we plotted the results of the bootstrap analysis in a cost-
effectiveness plane (CE-plane).12 Every dot in the CE-
plane represented one bootstrap replicate. The CE-plane
consisted of four quadrants. A dot on the right of the ver-
tical axis meant that oral anticoagulants were more effec-
tive, whereas a dot on the left side meant that aspirin was
more effective. Likewise, a dot above the horizontal axis
meant the costs of oral anticoagulants were higher,
whereas a dot below the horizontal axis implied the costs
of aspirin were higher.
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Because of the different effects of oral anticoagulants
and aspirin in patients with autologous vein grafts and
nonvenous grafts, a subgroup analysis was performed by
means of graft conduit.
RESULTS
Patients. The mean length of follow-up was 21
months, with a range from 0 to 45 months. Baseline char-
acteristics and risk factors were well balanced between the
treatment groups (Table I). The demographics of the
patients in the two samples were comparable with those of
the entire population in the Dutch BOA Study. The first
sample of patients from whom data were collected on
quality of life and resource use included 409 patients. Of
these patients, 379 had complete data for at least 1 month.
The proportion of patients with complete data was 100%
at month 3 and declined to 87% at month 18 and to 57%
at month 30. The number of patients with an event
included in the second sample was 609. The percentage of
patients with complete data was 65% at month 3, 86% at
month 12, and declined to 64% at month 30. The num-
ber of clinical outcome events in patients who no longer
filled in the questionnaires was approximately 20% higher
than in patients who completed all questionnaires.
Health outcomes. The number and types of events
in both treatment groups are presented in Table II. The
mean number of events was 1.22 (SD, 1.62) in the anti-
coagulant group and 1.27 (SD, 1.69) in the aspirin group;
the mean difference was 0.05 (95% CI, –0.08 to 0.18).
Event-free survival and QALYs were almost the same in
both treatment groups. In patients with vein grafts, event-
free survival and QALYs were higher in the anticoagulant
group. In patients with nonvenous grafts, QALYs were
higher in the anticoagulant group, whereas the event-free
survival was higher in the aspirin group. However, the dif-
ferences were small, and none of the differences were sta-
tistically significant.
Costs. The cost estimates associated with each event
and each health state after an event are presented in Table
III. These estimates were used as a means of calculating
the health care costs of all patients (Table IV). Mean costs
per patient were ` 6875 per patient in the anticoagulant
group and ` 7072 in the aspirin group. None of the dif-
ferences shown in Table IV were statistically significant.
Health state-related costs made-up 62% of the total costs.
Costs of medication in the aspirin group consisted of 1.5%
of the total costs, whereas costs of medication and moni-
toring in the anticoagulant group were 3.6% of the total
costs.
Cost-effectiveness. Because the differences in health
outcomes or costs were not statistically significant, the
CE-ratios were not calculated. The relationship between
costs and health outcomes and the uncertainty surround-
ing these estimates are shown in the CE-planes in the
Figure. The proportion of dots in each quadrant is
reported in the tables. In the Figure, a and b (event-free
survival and quality of life of all patients) show that almost
half of the replicates were in the right lower quadrant,
Table I. Baseline characteristics according to treatment
allocation
Oral anticoagulants Aspirin
Characteristic (n = 1326) (n = 1324)
Mean age (y) 69 69
Male sex 859 (65%) 839 (63%)
Indication
Intermittent claudication 665 (50%) 690 (52%)
Critical ischemia 661 (50%) 634 (21%)
Type of bypass
Femoropopliteal 1070 (81%) 1049 (79%)
Femorocrural/pedal 256 (19%) 275 (21%)
Graft material
Venous 784 (59%) 762 (58%)
Nonvenous 542 (41%) 562 (42%)
indicating that oral anticoagulants tended to have favor-
able health outcomes against lower costs in comparison
with aspirin. Likewise, c and d demonstrate that oral anti-
coagulants tended to be the favorable treatment in
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patients with venous bypass grafts. However, e and f
demonstrate that aspirin was less expensive and associated
with a higher event-free survival in patients with nonve-
nous grafts, whereas QALYs were higher in patients taking
Table II. Quality of life scores, events, event-free survival, and quality of life 
No. of events
All patients Vein graft Nonvenous graft
EQ-5D* AC† Aspirin AC Aspirin AC Aspirin
Health state after score (N = 1326) (N = 1324) (N = 784) (N = 762) (N = 542) (N = 562)
No event 0.68
Vascular intervention
Coronary artery bypass grafting surgery 0.58 16 13 10 9 6 4
Coronary artery angioplasty 0.58 12 10 8 7 4 3
Carotid thromboendarterectomy 0.58 6 10 6 7 0 3
Surgery of the aorta 0.58 11 6 7 4 4 2
Aortoiliac surgery 0.58 25 36 20 15 5 21
Infrainguinal surgery, contralateral leg 0.58 225 286 119 142 106 144
Infrainguinal surgery, ipsilateral leg 0.58 387 396 193 207 194 189
Other vascular surgery 0.58 3 4 1 1 2 3
All vascular interventions 685 761 364 392 321 369
Occlusion 0.58 308 323 112 156 196 167
Amputation 0.43 158 171 83 112 75 59
Hemorrhage 0.58 213 145 132 84 81 61
Stroke 0.45 30 46 20 28 10 18
Myocardial infarction 0.58 19 25 14 15 5 10
Death 0.00 211 205 125 127 86 78
Total 1624 1676 850 914 774 762
Event-free survival (y)* 1.10 1.09 1.15 1.13 1.02 1.03
Difference 0.01 0.02 –0.01
95% CI –0.07 to 0.08 –0.08 to 0.11 –0.08 to 0.13
QALYs† 1.06 1.05 1.09 1.07 1.03 1.02
Difference 0.01 0.02 0.01
95% CI –0.03 to 0.06 –0.04 to 0.07 –0.04 to 0.09
EQ-5D, Euroqol 5D; AC, oral anticoagulants; QALY, quality-adjusted life years.
*Mean follow-up: 21 months.
†A patient with perfect health who remained in the study for 21 months would have obtained a QALY score of 1.75.
Table III. Costs related to events and health states after an event in Euros
Costs per month of 
Type of event Event-related costs each health state
No event 0 250
After vascular intervention
Coronary artery bypass grafting surgery 18,000 450
Coronary artery angioplasty 4,100 450
Carotid thromboendarterectomy 4,100 450
Surgery of the aorta 5,000 450
Aortoiliac surgery 5,000 450
Infrainguinal bypass grafting surgery 4,500 450
Other vascular interventions 4,100 450
After other events
Occlusion 0 250
Amputation (first 6 mo) 11,500 1800
Amputation (after first 6 mo) 0 900
Hemorrhage 900 450
Stroke 11,500 900
Myocardial infarction 7,700 450
Death 3,200 0
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Table IV. Mean costs per patient per year in Euros
All patients Vein graft Nonvenous graft
AC Aspirin AC Aspirin AC Aspirin
Event-related costs 2322 2631 2115 2550 2621 2757
Health state-related costs 4304 4331 4255 4380 4380 4255
Drugs and monitoring 250 109 250 109 250 109
Total costs 6875 7072 6619 7039 7251 7121
Difference –196 –419 131
95% CI –746 to 343 –1166 to 289 –1111 to 774
AC, Oral anticoagulants.
CE-planes of oral anticoagulants versus aspirin (all costs in Euros).
oral anticoagulants. In none of the graphs does the pro-
portion of dots on one side of the vertical or horizontal
axis exceed 95%, demonstrating that none of the differ-
ences in health outcomes or costs were statistically signifi-
cant.
DISCUSSION
No differences in costs or effects between patients
treated with oral anticoagulants and patients treated with
aspirin after infrainguinal bypass surgery were shown by
means of the results of this study. Until this study, the
cost-effectiveness of these treatments had not been inves-
tigated. Economic evaluations were directed toward the
comparison of antithrombotic therapies in patients with
other manifestations of atherosclerosis, and most of these
studies were not made on the basis of trial data.13-17
Instead of collecting data throughout the entire study
period from all patients, we used a model to incorporate
the outcomes of all patients. The strength of this model is
that it allows the inclusion of all patients in the analysis,
without the need for collecting complete data on all
patients. The model makes use of data that were already
collected in the clinical study. The crucial additional inputs
in the model were the quality of life and costs associated
with each health state. The triggered design of the data col-
lection made it possible to base these values on most of the
patients with events. In a traditional design, this would
only be possible by collecting complete data on all patients.
The design of the data collection resulted in quality of
life and cost estimates at different months after random-
ization. Although the data collection included most
patients with events, it appeared to be hard to obtain reli-
able estimates of subsequent treatment costs of events.
Costs did not only differ strongly between patients, the
relationship between costs and events was also blurred by
the large number of combinations of events, the high costs
of patient care before an event, and the varying periods
between events. These factors, combined with the avail-
ability of only repetitive 1-month data, made it difficult to
determine which of the events were particularly related to
an increase in resource use and costs. Therefore, only esti-
mates of the event- and health state-related costs could be
made, and similar estimates were used in both treatment
groups. Considering the impact of an event, we consid-
ered it unlikely that we would find any differences in costs
and quality of life between treatment groups, independent
from events. Also, a test on the difference in costs and
effects in the random population of the first sample
showed no differences between the two treatment groups.
Another consequence of assigning fixed health states and
costs to events was that the uncertainty in the model-out-
comes only resulted from events, and not from uncertainty
around the quality of life or cost estimates. If, in addition
to the uncertainty around the events, the uncertainty
around these estimates was taken into account, it would
have increased the overall uncertainty of the outcomes.
Hence, this would have resulted in wider CIs and larger
areas of the CE-planes.
JOURNAL OF VASCULAR SURGERY
Volume 34, Number 2 Oostenbrink et al 259
Patients in the two samples who no longer filled in the
questionnaires had approximately 20% more clinical out-
come events than patients who completed all question-
naires. This could have influenced the estimates of quality
of life and costs associated with each health state. It should
be noted, however, that these estimates were obtained for
each health state separately. Even if patients who no longer
filled in the questionnaires had lower quality of life or
higher costs, the estimates associated with each health state
were not necessarily influenced. In addition, because simi-
lar estimates were used in both treatment groups, it seems
unlikely that the difference in costs or effects has been
influenced substantially by the follow-up in the samples.
When we estimated the costs of each health state after
an event, we had expected that the occurrence of an event
would lead to a higher resource use and a rise in subse-
quent treatment costs during the months after an event.
This expectation was not confirmed by means of the
resource use data in this study. Compared with patients
without events, patients with events not only had higher
costs after an event, but also before an event. This raises
questions about the association between costs and events.
Patients prone to have an event have higher medical
resource use already in the period before the event.
Patients who keep pain at rest after femorodistal bypass
grafting may illustrate this phenomenon. These patients
probably visit their vascular surgeon more often than
patients who have undergone successful bypass grafting.
Moreover, patients with rest pain probably get more diag-
nostic examinations, such as angiograms, to visualize the
native arteries and the graft, because a reoperation is con-
sidered. Because it is common to use event-driven models
in cost calculations, the validity of such models is ques-
tioned. We should be aware of this phenomenon when
using an event-driven model. Rather than only assigning
higher treatment costs to patients after an event, attention
should also be paid to the treatment costs before an event.
To determine the costs of monitoring patients, we set
up a separate costing study for the anticoagulation clinics.
We expected that the higher costs of monitoring in the
anticoagulant group would be an important factor that
could account for the difference in costs between the
treatment groups. However, the extra costs of monitoring
patients taking anticoagulants were only ` 200 per year,
which was very limited compared with the mean annual
costs of patients, which was ` 6970. Even patients with-
out events after the initial operation had yearly costs of 
` 3000. This implies that the extra costs of monitoring
patients taking anticoagulants do not play a decisive role in
comparing the cost-effectiveness of anticoagulants versus
aspirin after infrainguinal bypass surgery. In patients with
other manifestations of atherosclerosis, the additional
costs only become relevant when patients have low
resource use and costs. In patients with high resource use,
these costs will not contribute substantially to differences
in costs between treatment groups. Costs of monitoring in
this study were made on the basis of the Dutch situation,
with a highly effective system of anticoagulation clinics. In
several other countries, the costs of monitoring may be
higher. However, even when the costs of monitoring are
considerably higher than in the Netherlands, they still
make up a small amount of the total treatment costs.
Finally, we should note that our results apply to clini-
cal practice as performed in the Netherlands. Approxi-
mately half of our patients had intermittent claudication, a
condition not always considered to be an indication for
bypass surgery. Moreover, approximately 60% of our
patients received venous grafts, whereas this percentage
may be different in other settings.
In summary, we conclude that costs, event-free sur-
vival, and QALYs in patients after infrainguinal bypass
surgery were not different between patients treated with
aspirin and patients treated with oral anticoagulants. The
extra costs of monitoring patients with oral anticoagulants
were very limited and play no role in the decision for treat-
ment with either aspirin or oral anticoagulants.
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APPENDIX I. PARTICIPATING
INVESTIGATORS OF THE DUTCH BYPASS
ORAL ANTICOAGULANTS OR ASPIRIN (BOA)
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van Bockel, J. Buth, J. J. A. M. van den Dungen, B. C.
Eikelboom, J. A. Lawson, F. L. Moll, J. A. Rauwerda, P.
de Smit, M. J. D. Tangelder, H. van Urk, J. de Vries-
Goldschmeding (on behalf of the Federation of Dutch
Thrombosis Services).
Advisor: J. J. Sixma.
Trial Office: M. J. D. Tangelder (coordinator), E. A.
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Nie); Groene Hart Ziekenhuis Gouda (B. J. L. Kothuis, J. C.
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W. C. de Jonge, J. W. D. de Waard); Medisch Centrum
Leeuwarden (D. C. Busman, R. Leemans, J. A. Zijlstra);
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Ziekenhuis Maastricht (P. J. E. H. M. Kitslaar, J. H. M.
Tordoir); St Antonius Ziekenhuis Nieuwegein (F. L. Moll,
H. D. W. M. van de Pavoordt, R. P. Tutein Nolthenius);
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Buskens, J. A. van der Vliet); Canisius-Wilhelmina
Ziekenhuis Nijmegen (W. B. Barendregt, J. A. M.
Hoogbergen, L. A. A. van Knippenberg, A. G. A. Spelde);
Waterland Ziekenhuis Purmerend (Th. A. A. van den
Broek, G. A. Vos); St Laurentius Ziekenhuis Roermond (E.
F. A. de Haan, C. M. Nuyens); Academisch Ziekenhuis
Dijkzigt Rotterdam (L. M. C. van Dortmond, N. A. J.
Dubois, M. R. H. M. van Sambeek, H. van Urk); Ikazia
Ziekenhuis Rotterdam (R. U. Boelhouwer, H. F. Veen); St
Clara Ziekenhuis Rotterdam (J. M. Hendriks, A. A. E. A.
de Smet, T. I. Yo); St Franciscus Gasthuis Rotterdam (W. B.
van Gent, C. H. A. Wittens); Maaslandziekenhuis Sittard
(A. G. M. Hoofwijk, W. H. V. M. L’Ortije, H. J. G.
Stroeken); Merwedeziekenhuis Sliedrecht (P. J.
Mouthaan); St Elisabeth Ziekenhuis Tilburg (D. P. van
Berge Henegouwen, J. C. Breek, J. F. Hamming);
Tweesteden Ziekenhuis Tilburg (S. J. Brenninkmeijer, G. P.
Gerritsen, S. E. Kranendonk); Academisch Ziekenhuis
Utrecht (J. D. Blankensteijn, B. C. Eikelboom, B. H. P.
Elsman, R. W. H. van Reedt Dortland, J. J. F. Steijling, Th.
J. M. V. van Vroonhoven); Ziekenhuis Overvecht Utrecht
(B. C. V. M. Disselhoff); St Joseph Ziekenhuis Veghel (C.
J. Broers, H. A. P. A. de Geus); St Joseph Ziekenhuis
Veldhoven (M. H. M. Bender, J. A. Charbon, Th. J. van
Straaten); St Maartens Gasthuis Venlo (P. F. Verhagen);
Holy Ziekenhuis Vlaardingen (E. R. Snijder);
Streekziekenhuis Koningin Beatrix Winterswijk (A. A. Vafi);
Hofpoort Ziekenhuis Woerden (E. Bakker, W. van
Eesteren); Kennemer Gasthuis locatie Zeeweg IJmuiden (J.
J. Petit); Stichting Ziekenhuis De Heel Zaandam (R. A.
Cohen, R. P. Strating); Streekziekenhuis Zevenaar (R. F. de
Haan, P. E. Reenalda, C. Sieswerda, J. van Wijk); ‘t Lange
Land Ziekenhuis Zoetermeer (M. T. Sjer, L. J. J. P.
Speetjens); Het Nieuwe Spittaal Zutphen (R. H. Schreve);
St Sophia Ziekenhuis Zwolle (P. J. G. Jörning, M.C.
Kerdel); Ziekenhuis De Weezenlanden Zwolle (A. M.
Blomme, E. A. Kole).
APPENDIX II. UNIT COSTS
Unit costs of inpatient hospital days, visits to the con-
sultant, infrainguinal bypass grafting surgery, and the
monitoring of patients in the oral anticoagulant group
were determined by means of detailed costing studies,
because these items were expected to have the largest con-
tribution to the incremental and total costs. The unit costs
of inpatient days were calculated in two university hospi-
tals and two general hospitals and included the costs of
physicians, nursing, additional medication, diagnostic pro-
cedures, and buildings, equipment, and overhead. The
unit costs of infrainguinal bypass surgery were calculated
by means of multiplying the estimated duration of surgery
with the cost per minute of the operating theater. The
average duration of surgery was made on the basis of 
the registration system of the operating theaters and on
the basis of earlier research.7 The resulting unit costs are
presented in Table V.
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APPENDIX III. BOOTSTRAPPING
Several authors have recommended the use of non-
parametric bootstrapping to estimate CIs around the
incremental CE-ratios.9-11 One of the advantages of this
method is that it does not depend on parametric assump-
tions of the underlying sampling distribution. The boot-
strap method consists of these steps10:
1. Sample with replacement NA pairs of costs and effects
of patients in treatment group A, in which NA is the
number of patients in group A.
2. Calculate the mean costs and effects of this new sam-
ple.
3. Repeat these two steps in treatment group B.
4. Calculate the differences in mean costs and effects
between the samples drawn from treatment group A
and those from group B and calculate the incremental
CE-ratio by dividing the difference in costs by the dif-
ference in effects.
The four steps reflect one bootstrap replicate. In this
study, 1000 bootstrap replicates were obtained. CIs of the
CE-ratio were obtained with the percentile method. This
method implies that the 1000 replicates are sorted in
ascending order and that the 95% CI constitutes of the
25th and 975th observations.
Table V. Unit costs in Euros
Type of resource use Unit costs
Vascular surgery
Coronary artery bypass grafting surgery 8000
Coronary artery angioplasty 2700
Carotid thromboendarterectomy 1250
Surgery of the aorta 2220
Aortoiliac surgery 2150




















Monitoring anticoagulant patients 200
